特寶生物(688278.SH):益佩生通過優化選擇非N-末端位點為主的修飾組分,提高生物學比活性,延長半衰期
格隆匯6月11日丨特寶生物(688278.SH)在互動平台表示,益佩生是公司自主研發的一款採用40kD Y型分支聚乙二醇進行單分子修飾的全新一代長效生長激素,適用於治療3歲及以上兒童的生長激素缺乏症所致的生長緩慢。益佩生通過優化選擇非N-末端位點為主的修飾組分,提高生物學比活性,延長半衰期,從而在保證療效的同時,降低給藥劑量,獲得更佳的長期藥物安全性。與短效劑型每日給藥相比,益佩生可實現每週給藥一次,降低了患者接受治療時的用藥頻次,有效緩解身心負擔,提高用藥依從性,為生長激素缺乏症等相關疾病患者提供更加便捷有效的治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.